Financial Performance - The company's revenue for Q3 2021 reached ¥143,270,966.07, representing a 22.01% increase compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2021 was ¥13,021,687.46, a 3.28% increase year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 14.59% to ¥9,423,092.27 in Q3 2021[2]. - Total operating revenue for Q3 2021 reached CNY 445,950,409.88, a 39.5% increase from CNY 319,492,200.40 in the same period last year[20]. - Net profit attributable to the parent company was CNY 54,065,347.95, representing a 72.8% increase compared to CNY 31,290,293.73 in Q3 2020[21]. - Operating profit for the period was CNY 52,707,982.29, an increase of 57.3% from CNY 33,492,300.59 in the previous year[20]. - The total profit for the period was CNY 60,475,188.00, up 68.9% from CNY 35,772,929.41 in Q3 2020[20]. - Earnings per share for the quarter were CNY 0.53, compared to CNY 0.36 in the same quarter last year, marking a 47.2% increase[21]. Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥1,055,432,040.81, reflecting a 31.20% increase from the end of the previous year[2]. - The company's current assets reached CNY 750,247,277.45, up from CNY 579,642,443.60 at the end of 2020, indicating an increase of about 29.4%[15][17]. - The cash and cash equivalents increased significantly to CNY 122,819,652.53 from CNY 28,963,697.71, marking a growth of approximately 324.5%[15][17]. - Accounts receivable rose to CNY 247,424,461.89, compared to CNY 207,182,890.78 at the end of 2020, reflecting an increase of about 19.4%[15][17]. - Inventory levels increased to CNY 261,923,586.30 from CNY 200,739,033.05, which is an increase of approximately 30.5%[15][17]. - The total liabilities of the company were CNY 267,576,085.42, slightly up from CNY 264,579,247.03 at the end of 2020, showing a marginal increase of about 1.0%[17]. - The total equity attributable to shareholders increased to CNY 782,787,729.54 from CNY 534,540,315.19, representing a growth of approximately 46.4%[17]. Cash Flow and Investments - The company reported a significant increase in cash flow from operating activities, with a net cash flow of ¥1,227,234.45 for the first nine months, although it showed a decline of 91.28% compared to the previous year[2]. - Cash flow from operating activities generated a net amount of CNY 1,227,234.45, a significant decrease from CNY 14,073,404.57 in the same quarter last year[24]. - The company raised CNY 210,160,000.00 from investment activities, a significant increase from CNY 5,400,017.80 in the previous year[24]. Research and Development - Research and development expenses for the first nine months of 2021 rose by 125.20% to ¥24,512,055.83, indicating increased investment in innovation[7]. - Research and development expenses increased to CNY 24,512,055.83, compared to CNY 10,884,586.20 in the same period last year, reflecting a 125.5% rise[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,789, indicating a broad base of investor support[10]. - The company reported a total of 87,773,991 shares under lock-up agreements, with various shareholders holding significant amounts[12][14]. - The company has committed to releasing certain locked shares on specified dates, with the largest block being 36,567,000 shares held by Xi Zuobin, set to be released on April 9, 2024[12][14]. Government Support - The company received government subsidies amounting to ¥4,136,095.05 in Q3 2021, contributing to its financial performance[5]. Financial Stability - The company has maintained a stable financial position with a current ratio indicating sufficient liquidity to meet short-term obligations[15][17].
共同药业(300966) - 2021 Q3 - 季度财报